After increasing for many years, prostate cancer incidence trends are stabilising or decreasing in the last observed 5 years (approximately after 2005), likely due in part to clinical caution in use of PSA testing given intrusive investigation and the possibility of unnecessary diagnosis of clinically irrelevant disease [52]. Here, KLK3 is linked to prostate carcinoma.